Antigenics retransmettra sur Internet l'Assembl?e G?n?rale Annuelle 2005 des actionnaires.

Business Editors/Health/Medical Writers BIOWIRE2K

NEW YORK--(BUSINESS WIRE)-- 25 mai 2005--Antigenics Inc. (NASDAQ: AGEN) invite les investisseurs et le public à écouter une retransmission audio de l’Assemblée Générale Annuelle 2005 de ses actionnaires le 1er juin 2005 à 17 heures (heure de la côte Est des États-Unis). Ce webcast sera disponible sur le site de la Société à l’adresse suivante : www.antigenics.com/webcast/, et sera également accessible en différé environ deux heures après la tenue de l’Assemblée.

(BW)(NY-ANTIGENICS)(AGEN) Antigenics to Webcast 2005 Annual Shareholders Meeting

Business Editors/Health/Medical Writers BIOWIRE2K

NEW YORK--(BUSINESS WIRE)--May 25, 2005--Antigenics Inc. (NASDAQ: AGEN) invites investors and the general public to listen to a live audio webcast of its 2005 Annual Shareholders Meeting at 5:00 p.m. ET on Wednesday, June 1, 2005. The webcast will be accessible from the company's website at www.antigenics.com/webcast/ and will be archived and available for replay approximately two hours after the meeting

Antigenics is working to develop personalized immunotherapeutics and revolutionary treatments for cancers and infectious diseases. The company's lead product candidate is Oncophage(R) (HSPPC-96), a late-stage, personalized cancer vaccine being evaluated in several indications, including renal cell carcinoma and metastatic melanoma

Antigenics' portfolio of investigational products also includes AG-858 (HSPPC-70), a personalized cancer vaccine in Phase 2 development; two Phase 2 liposomal cancer treatments, Aroplatin(TM) and ATRA-IV; and AG-702/AG-707, a Phase 1 genital herpes program. For more information about Antigenics, please visit www.antigenics.com.

CONTACT: Antigenics Inc

Investor Relations Jack Howarth, 212-994-8244 [email protected]

or

Corporate Communications Sunny Uberoi, 212-994-8206 [email protected]

KEYWORD: NEW YORK Biomedical

INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY BANKING CONFERENCE CALLS

SOURCE: Antigenics Inc.